New Releases from NCBI BookshelfTrabectedin: Reimbursement Recommendation [Internet].Trabectedin: Reimbursement Recommendation [Internet].
What Is the Reimbursement Recommendation for Trabectedin?
Uncategorized
January 13, 2026
Uncategorized
New Releases from NCBI BookshelfAbemaciclib (Verzenio): Therapeutic area: HR-positive, HER2-negative advanced or metastatic breast cancer: Reimbursement Review [Internet].Abemaciclib (Verzenio): Therapeutic area: HR-positive, HER2-negative advanced or metastatic breast cancer: Reimbursement Review [Internet].
Post Content
Uncategorized
New Releases from NCBI BookshelfInavolisib (Itovebi): Indication: Inavolisib in combination with palbociclib and fulvestrant is indicated for the treatment of adult patients with endocrine resistant, PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment: Reimbursement Recommendation [Internet].Inavolisib (Itovebi): Indication: Inavolisib in combination with palbociclib and fulvestrant is indicated for the treatment of adult patients with endocrine resistant, PIK3CA-mutated, hormone receptor–positive, human epidermal growth factor receptor 2–negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Itovebi in combination with palbociclib (PAL) and fulvestrant (FUL) be reimbursed by public drug
